Related Experiment Videos
Recurrent vulvovaginal candidiasis
1Division of Women's Health, Department of Obstetrics and Gynecology, Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA. cmacneill@psu.edu
Current Women'S Health Reports
|July 13, 2002
Summary
Recurrent vulvovaginal candidiasis, often caused by non-albicans species resistant to antifungals, requires detailed diagnosis and prolonged treatment. Identifying host factors may enable targeted therapies for chronic pain syndromes.
Area of Science:
- Mycology
- Infectious Diseases
- Women's Health
Background:
- Over-the-counter antifungal use has increased recurrent vulvovaginal candidiasis (RVVC) cases.
- RVVC is linked to chronic vulvovaginal pain syndromes.
- Non-albicans Candida species are increasingly implicated in RVVC.
Purpose of the Study:
- To highlight the diagnostic challenges and therapeutic needs in RVVC.
- To emphasize the importance of accurate species identification for effective treatment.
- To discuss the role of prolonged antifungal therapy and future research directions.
Main Methods:
- Review of current literature on vulvovaginal candidiasis diagnosis and treatment.
- Analysis of the increasing prevalence of non-albicans Candida species.
- Discussion of antifungal resistance patterns and therapeutic strategies.
Main Results:
- Non-albicans Candida species are frequently resistant to standard azole antifungals.
- Accurate species identification via fungal culture is crucial for appropriate treatment.
- Long-term suppressive therapy (≥6 months) is often necessary for managing RVVC.
Conclusions:
- Aggressive, diagnosis-driven therapy is essential for RVVC and associated pain syndromes.
- Fungal cultures are vital for identifying non-albicans species and guiding treatment.
- Further research into host factors may lead to personalized therapies for RVVC recurrence.